Serologic profile and mortality rates of scleroderma renal crisis in Italy

Journal of Rheumatology

Volumn 36, Issue 7, 2009, Pages 1464-1469

  Codullo, Veronica ^a   Cavazzana, Ilaria ^b   Bonino, Claudia ^a   Alpini, Claudia ^c   Cavagna, Lorenzo ^a   Cozzi, Franco ^d   Del Papa, Nicoletta ^e   Franceschini, Franco ^b   Guiducci, Serena ^f   Morozzi, Gabriella ^g   Ruffatti, Amelia ^d   Ferri, Clodoveo ^h   Giacomelli, Roberto ⁱ   Matucci Cerinic, Marco ^f   Valentini, Gabriele ^j   Montecucco, Carlomaurizio ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF L'AQUILA   (Italy)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

Anti RNA polymerases I III; Anti topoisomerase I; Autoantibodies; Scleroderma renal crisis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; ITALY; KIDNEY DISEASE; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCLERODERMA RENAL CRISIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES; ANTIBODIES, ANTINUCLEAR; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA POLYMERASE I; RNA POLYMERASE II; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 67650459130     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080806     Document Type: Article

References (22)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
2. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum antibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
3. Codullo V, Bardoni A, Salvini R, Montecucco C. Antinuclear antibodies in systemic sclerosis. Future Rheumatology 2006;1:365-71.
4. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin concverting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
5. Steen VD. Scleroderma renal crisis. Rheum Dis Clin N Am 2003;29:315-33.
6. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
7. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91:1399-404.
8. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
9. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 2002;81:139-53.
10. Bardoni A, Rossi P, Salvini R, Bobbio-Pallavicini F, Caporali R, Montecucco C. Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003;21:301-6.
11. Meyer O, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical feature in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.
12. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
13. Codullo V, Morozzi G, Bardoni A, et al. Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis. Clin Exp Rheumatol 2007;25:373-7.
14. La Montagna G, Baruffo A, Maja L, et al. Scleroderma renal crisis. Analysis of prevalence in a large Italian series. J Clin Rheumatol 1997;3:188-92.
15. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
16. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study in 50 patients. Ann Rheum Dis 2008;67:110-6.
17. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100:485-94.
18. Picillo U, Migliaresi S, Vatti M, Marcialis MR, Ferruzzi AM, Tirri G. Demographic differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1993;36:1332-4.
19. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
20. Harvey GR, Butts S, Rands Al, Patel Y, McHugh NJ. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999;117:395-402.
21. Steen VD, Medsger TA Jr. Changes in causes of death, 1972-2002. Ann Rheum Dis 2007;66:940-4.
22. Teixeira L, Mahr A, Bereznè A, Noel L, Guillevin L, Mouthon L. Scleroderma renal crisis, still a life-threatening complication. Ann NY Acad Sci 2007;1108:249-58.